SLC2A1 and neoplasm: Thus, we first treated Ccne1+ tumor-bearing immunocompetent mice (immune-excluded, chemo-resistant model) with a standard regimen of doxorubicin (DOX) (6 mg/kg), alone or in combination with the GLUT1 inhibitor (GLUT1i, BAY-876, 5 mg/kg) (Fig. 6a).